TECENTRIQ Vials (1,200 mg/20 ml)

Similar documents
XOLAIR(R) PFS (150 mg)

GAZYVA(R) Vials (1,000 mg/40 ml)

HERCEPTIN HYLECTATM Vials (600 mg/5 ml) SC

XOLAIR(R) Vials (150 mg)

LUCENTIS(R) Vials (0.5 mg/0.05 ml)

RITUXAN(R) Vials (100 mg/10 ml)

HERCEPTIN(R) Vials (150 mg)

RITUXAN(R) Vials (100 mg/10 ml)

RITUXAN HYCELATM Vials (1,400 mg/23,400 Units per 11.7 ml)

ACTEMRA(R) Sterile Concentrate for Injection (80 mg)

ACTEMRA(R) Sterile Concentrate for Injection (400 mg)

AVASTIN(R) Vials (400 mg)

CATHFLO ACTIVASE(R) Vials (2 mg)

ACTIVASE Vials (100 mg)

Trastuzumab Relevant identified uses of the substance or mixture and uses advised against

XOFLUZATM (Baloxavir Marboxil) Tablets 20mg

PEGASYS(R) Prefilled Syringe (180 mcg/0.5 ml)

ROFERON-A PFS 3 M IU/0.5 ml

HERCEPTIN Vials 60 mg

TAMIFLU(R) Capsules (75 mg)

NeoRecormon PFS IU/0.6 ml

NeoRecormon PFS 2000 IU/0.3 ml

ANEXATE Ampoules 0.5 mg/5 ml

ESBRIET(R) Capsules (267 mg)

DILATREND Tablets 6.25 mg

Interferon alfa-2a Solution

TAMIFLU(R) Capsules (75 mg)

DORMICUM Ampoules 5 mg/5 ml

ESBRIET F.C. Tablets 801 mg

LEXOTAN Tablets 3 mg

LEXOTAN Capsules 1.5 mg

DORMICUM F.C. Tablets 15 mg

KLONOPIN(R) Tablets (2 mg)

VALCYTE(R) Powder for Constitution

KLONOPIN(R) Tablets (2.0 mg)

PEGASYS(R) Vials (0.135 mg/ml)

ROACCUTANE Capsules 40 mg

FUZEON Vials 90 mg Relevant identified uses of the substance or mixture and uses advised against

SAFETY DATA SHEET Issuing Date 31 May 2017 Revision Date 27 June 2017 Version 2.3

VALIUM Tablets 5 mg Relevant identified uses of the substance or mixture and uses advised against

SAFETY DATA SHEET according to Regulation (EC) No. 1907/2006 Amega Duo Version 2 (UK) Issuing date: 2014/04/04

SAFETY DATA SHEET according to Regulation (EC) No. 1907/2006 Depitox Version 8 (UK) Issuing date: 2011/01/06

ROACCUTANE Capsules 10 mg

Safety Data Sheet Rapicide PA Part B (RTU) Revision Date: Sourethweg PC HEERLEN The Netherlands TEL

: Consumer Care Center: UK Ireland

SAFETY DATA SHEET according to Regulation (EC) No. 1907/2006 Depitox Version 8 (UK) Issuing date: 2014/01/23

Oseltamivir phosphate

: Bonide Mite X Ready to Use

COPEGUS(R) F.C. Tablets (200 mg)

VALIUM Tablets 10 mg

COPEGUS Tablets 200 mg

CHEMTREC SECTION 2: HAZARDS IDENTIFICATION. 2.1 Classification of Substance or Mixture Classification (GHS-US) Not Classified

SAFETY DATA SHEET. Calcium acetate Ref.50274/1.1/REG_EU/EN Revision Date: Previous date: Print Date:

: esemtan body lotion

INVIRASE(R) Capsules (200 mg)

SAFETY DATA SHEET Greenline Plus Washroom Cleaner RTU

: Go Away! Deer & Rabbit Repellent RTU

SAFETY DATA SHEET according to Regulation (EC) No. 1907/2006 DUPLOSAN KV Version 4 (UK) Issuing date: 2014/01/24

SAFETY DATA SHEET Carpet Mousse

BLUEBERRY LIQUID FRUIT EXTRACT

Safety Data Sheet according to Federal Register / Vol. 77, No. 58 / Monday, March 26, 2012 / Rules and Regulations

SECTION 1: PRODUCT AND COMPANY INFORMATION SECTION 2: HAZARD(S) IDENTIFICATION

SECTION 1. Identification of the substance/mixture and of the company/undertaking. This product is a laboratory preparation for educational use only.

XENICAL Capsules 120 mg

SAFETY DATA SHEET. SECTION 1: Identification of the substance/mixture and of the company/undertaking

SAFETY DATA SHEET Patio Seal Porous Plus

: Phosphate Standard, 1000ppm PO4

: PLANT HEALTH technologies Volare DC

: BIO 101 Bio-Zyme Cleaner/Deodorant

: PAD LOCK. SECTION 1: Identification. SECTION 2: Hazard(s) identification Identification Recommended use and restrictions on use

PHENOL RED PHOTOMETER

: Polyethylene glycol

Safety Data Sheet according to Federal Register / Vol. 77, No. 58 / Monday, March 26, 2012 / Rules and Regulations

SECTION 1. Identification of the substance/mixture and of the company/undertaking

Telephone : : : (24 H) Risk of serious damage to eyes.

Reagent R1, Reagent R2, Calibrators and Controls

SAFETY DATA SHEET SYNTON PAO 40

1.2 Relevant identified uses of the substance or mixture and uses advised against Use of the Substance/Mixture : Air care products

LORANN OILS, INC Aurelius Road Office (800) Lansing, MI Fax (517)

XENICAL Capsules 120 mg

: Focus MP 11 Multi-Purpose Cleaner

Version 3.0 Print Date 2011/02/23 Revision Date 2011/02/ Identification of the substance/mixture and of the company/undertaking

LORANN OILS, INC Aurelius Road Office (800) Lansing, MI Fax (517)

: Sodium Sulfite, 5% w/v

: Bonide Rot Stop Concentrate

SAFETY DATA SHEET Boelube

SAFETY DATA SHEET. SECTION 1: Identification of the substance/mixture and of the company/undertaking

Safety data sheet according to 1907/2006/EC, Article 31

Safety data sheet according to 1907/2006/EC, Article 31

SAUNA MILK EUCALYPTUS

SAFETY DATA SHEET. 1/7 Supersedes date: SECTION 1: IDENTIFICATION OF THE SUBSTANCE/MIXTURE AND OF THE COMPANY/UNDERTAKING

LORANN OILS, INC Aurelius Road Office (800) Lansing, MI Fax (517)

: CER-PCMO. SECTION 1: Identification of the substance/mixture and of the company/undertaking. SECTION 2: Hazards identification

SAFETY DATA SHEET Revised edition no : 0 SDS/MSDS Date : 27 / 7 / 2013

SOLVENT GREEN 3 CAS NO MATERIAL SAFETY DATA SHEET SDS/MSDS

SECTION 1: Identification of the substance/mixture and of the company/undertaking. SECTION 2: Hazard(s) identification

Safety Data Sheet European Format

Potassium Dihydrogen Ortho Phosphate CAS No MATERIAL SAFETY DATA SHEET SDS/MSDS

Section 1: Identification of the Substance/Mixture and of the Company/Undertaking 1.1 Product Identifier

Transcription:

Safety Data Sheet TECENTRIQ Vials (1,200 mg/20 ml) SECTION 1: Identification of the substance/mixture and of the company/undertaking 1.1. Product identifier Product name Product code Synonyms TECENTRIQ Vials (1,200 mg/20 ml) SAP-10154949 - Drug Product - TECENTRIQ(R) (1,200 mg/20 ml) - MPDL3280A *1 1.2. Relevant identified uses of the substance or mixture and uses advised against Use - pharmaceutical active substance (antineoplastic) *1 1.3. Details of the supplier of the safety data sheet Company information Enquiries: Genentech, Inc. 1 DNA Way South San Francisco USA-CA 94080 United States of America Phone 001-(650) 225-1000 E-Mail info.sds@roche.com US Chemtrec phone: (800)-424-9300 Local representation: 1.4. Emergency telephone number Emergency telephone number US Chemtrec phone: (800)-424-9300 *1 SECTION 2: Hazards identification Classification of the substance or mixture / Label elements GHS Classification no classification and labelling according to GHS Other hazards Page: 1/7

SECTION 3: Composition/information on ingredients Ingredients Concentration GHS-Classification (pure ingredient) 1380723-44-3 L-Histidine 71-00-1 Sucrose 57-50-1 9005-64-5 5.43 % 0.28 % 3.72 % 0.04 % *1 SECTION 4: First aid measures 4.1. Description of first aid measures Eye contact Skin contact Inhalation - rinse immediately with tap water for at least 20 minutes - open eyelids forcibly - remove immediately contaminated clothes, wash affected skin with water and soap - do not use any solvents - remove the casualty to fresh air - in the event of symptoms get medical treatment 4.2. Most important symptoms and effects, both acute and delayed 4.3. Indication of any immediate medical attention and special treatment needed to physician - treat symptomatically SECTION 5: Firefighting measures 5.1. Extinguishing media Suitable extinguishing media - water spray jet, dry powder, foam, carbon dioxide - adapt extinguishing media to surrounding fire conditions Flash point (liquid) > 110 C *2 Page: 2/7

5.2. Special hazards arising from the substance or mixture Specific hazards - no particular hazards known 5.3. Advice for firefighters Protection of fire-fighters - precipitate gases/vapours/mists with water spray *2 SECTION 6: Accidental release measures 6.1. Personal precautions, protective equipment and emergency procedures Personal precautions - no special precautions required 6.2. Environmental precautions Environmental protection - no special environmental precautions required 6.3. Methods and material for containment and cleaning up Methods for cleaning up - collect liquids by means of sand, earth or another suitable material - rinse with plenty of water SECTION 7: Handling and storage 7.1. Precautions for safe handling Technical measures Suitable materials - no special measures necessary if stored and handled as prescribed - glass, enamel, stainless steel 7.2. Conditions for safe storage, including any incompatibilities Storage conditions - 2-8 C - protected from heat and light - do not shake solution Validity Packaging materials - in the unopened original container, after opening the content should be used within a short period, see expiry date on the label - vials Page: 3/7

SECTION 8: Exposure controls/personal protection 8.1. Control parameters Threshold value (Roche) air - IOEL (Internal Occupational Exposure Limit): 0.220 mg/m3 *1 8.2. Exposure controls Respiratory protection Hand protection Eye protection - Respiratory protection is recommended as a precaution to minimize exposure. Effective engineering controls are considered to be the primary means to control worker exposure. Respiratory protection should not substitute for feasible engineering controls. - respiratory protection not necessary during normal operations - protective gloves (eg made of neoprene, nitrile or butyl rubber) - safety glasses *1 SECTION 9: Physical and chemical properties 9.1. Information on basic physical and chemical properties Color Form colorless to slightly yellow sterile liquid Solubility 38.2 g/l, water (20 C) *3 100 g/l, water *2 Partition coefficient log P ow -3.32 (octanol/water) *3 ph value 5.8 9.2. Other information *2 *3 L-Histidine SECTION 10: Stability and reactivity 10.1. Reactivity Page: 4/7

10.2. Chemical stability Stability - does not contain any antimicrobial preservative; therefore, care must be taken to ensure the sterility of the prepared solution 10.3. Possibility of hazardous reactions 10.4. Conditions to avoid 10.5. Incompatible materials 10.6. Hazardous decomposition products SECTION 11: Toxicological information 11.1. Information on toxicological effects Acute toxicity - not bioavailable by oral administration *1 - LD 50 > 15 000 mg/kg (oral, rat) *3 - LD 50 > 32 850 mg/kg (oral, rat) (OECD No. 401) *2 - LD 50 29 700 mg/kg (oral, rat) *4 Local effects - skin: non-irritant (rabbit; OECD No. 404) *2 Sensitization anaphylactic reactions may occur following the intravenous application of proteins; after inhalative exposure no cases of hypersensitivity have been described *1 Mutagenicity Carcinogenicity - - negative, both with and without metabolic activation (OECD No. 476 (Mammalian Cell Gene Mutation Test)) *2 no information available Reproductive toxicity STOT-single exposure - critical exposure in human after parenteral administration only - parenteral administration to pregnant women can cause fetal harm*1 STOT-repeated exposure Aspiration hazard Page: 5/7

- therapeutic dose (i.v.): 15 mg/kg/3w *1 *1 *2 *3 *4 L-Histidine Sucrose SECTION 12: Ecological information 12.1. Toxicity Ecotoxicity - monoclonal antibodies are proteins with highly specific affinity to a certain antigen; therefore, no appreciable ecotoxic potential is to be expected *1 12.2. Persistence and degradability Ready biodegradability - globular proteins are generally well biodegradable *1 - readily biodegradable 60.3 %, 28 d (Manometric Respirometry Test, OECD No. 301 F) *2 12.3. Bioaccumulative potential 12.4. Mobility in soil 12.5. Results of PBT and vpvb assessment 12.6. Other adverse effects *1 *2 SECTION 13: Disposal considerations 13.1. Waste treatment methods Waste from residues - observe local/national regulations regarding waste disposal - drain very small quantities into wastewater treatment plant Page: 6/7

SECTION 14: Transport information - not classified as Dangerous Good according to the Dangerous Goods Regulations, proper shipping name non-regulated SECTION 15: Regulatory information 15.1. Safety, health and environmental regulations/legislation specific for the substance or mixture TSCA Status Reporting Requirements - FDA Exemption - not on inventory - The United States Environmental Protection Agency (USEPA) has not established a Reportable Quantity (RQ) for releases of this material. - In New Jersey, report all releases, which are likely to endanger the public health, harm the environment or cause a complaint, to the NJDEPE Hotline and to local officials. - State and local regulations vary and may impose additional reporting requirements. SECTION 16: Other information - none Edition documentation - changes from previous version in sections 8 The information in this safety data sheet is based on current scientific knowledge. It should not be taken as expressing or implying any warranty concerning product characteristics. Page: 7/7